Zoledronic acid (Zometa)
. Draft fact sheet, awaiting Henry's approval. Items marked [check] must be verified before publishing.
← All drugs · Search the portal
Facts
| Topic | Fact | Source (access date) |
|---|---|---|
| First approval | US 20 Aug 2001 (Zometa, Novartis); EU 20 Mar 2001; generics in EU | Drugs@FDA via openFDA, https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA021223 (accessed 4 Nov 2026); EMA medicines report, https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx (accessed 4 Nov 2026) |
| Mechanism | Nitrogen-containing bisphosphonate; binds bone mineral and inhibits osteoclast-mediated bone resorption | eMC SmPC https://www.medicines.org.uk/emc/product/210/smpc (accessed 4 Nov 2026); eMC SmPC https://www.medicines.org.uk/emc/product/7205/smpc (accessed 4 Nov 2026) |
| Use in osteosarcoma | Tested first line in OS2006; not recommended (ESMO 2021) | doi:10.1016/S1470-2045(16)30096-1; ESMO via treatment_by_country.md |
| Combined with | Methotrexate-based chemotherapy (under 18) or doxorubicin, ifosfamide, cisplatin (over 25) in OS2006 | doi:10.1016/S1470-2045(16)30096-1 abstract (4 Nov 2026) |
| Results | OS2006, 318 patients aged 5-50, 40 French centres: 3-year EFS 57.1% with v 63.4% without; HR 1.36; stopped for futility | treatment_by_country.md; abstract above |
| Side effects | Kidney toxicity, low calcium, jaw osteonecrosis, fever and flu-like (acute phase) reaction, nausea, tiredness, bone pain | eMC SmPC https://www.medicines.org.uk/emc/product/7205/smpc (accessed 4 Nov 2026); openFDA zoledronic acid label (accessed 4 Nov 2026) |
| Owner | Novartis originator; EU Zometa holder now Phoenix Labs; generic | EMA medicines report, https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx (accessed 4 Nov 2026) |
| Regulatory | US, EU, UK: bone complications of cancer, high calcium in cancer, myeloma. China: Novartis Aclasta import licence HJ20181132 (5 mg, osteoporosis); domestic oncology-strength generics e.g. Kelun H20203010 (4 mg) and H20183157 (5 mg, approved 31 May 2018). Not osteosarcoma | National Population Health Data Center drug database, https://pharm.ncmi.cn/zysjk/ypjkyp/202312/t20231205_399737.html (accessed 4 Nov 2026); NMPA approval number H20183157 via yaopinnet.com mirror, https://www.yaopinnet.com/h/h57/H20183157.htm (accessed 4 Nov 2026); official NMPA register (datasearch.nmpa.gov.cn) returned HTTP 412 to automated access |
Hypotheses and open points (not established fact)
- None recorded.